Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 23
GLP-1 FAERS safety signals explained
A 2026 pharmacovigilance paper examined 243,114 FAERS reports for GLP-1 agents. Tirzepatide led at 133,100. What the signal patterns mean.
GLP-1 Drugs in Children Ages 8-11: Trends
A 3.5-million-child Pediatrics study found GLP-1 prescriptions for 8-to-11-year-olds grew 310-fold from 2019 to 2026, all off-label.
GLP-1 Receptor Agonists and Sleep Apnea
Tirzepatide holds a US FDA approval for sleep apnea backed by SURMOUNT-OSA data. Here is what the evidence supports for the GLP-1 receptor agonist class.
Insulin resistance to incretin agonism: T2D
A 2026 review maps the path from insulin resistance to T2DM prevention, covering metformin, GLP-1 agonists, tirzepatide, and retatrutide.
Semaglutide mouse lifespan: what we know
A 2026 Nature study found semaglutide extended lifespan in older female mice by ~100 days. Here is what the finding means, and what it does not.
Semaglutide, obesity, and chronic migraine
A 2026 letter in Headache argues semaglutide may break a loop in which obesity worsens migraine and fasting-driven avoidance triggers more attacks.
How labs verify semaglutide in the pen
A 2026 J. Chromatography B review maps analytical methods for semaglutide in pharmaceutical formulations and plasma.
Semaglutide oral bioavailability explained
Oral semaglutide achieves 0.4% to 1% bioavailability versus 89% for the injection. A 2026 review in Pharmaceutical Research explains the barriers.
Semaglutide extended lifespan in old mice
A Nature study found late-life semaglutide extended median lifespan by 12% in aged female mice, which is not proof the drug slows aging in people.
Semaglutide's direct reproductive effects
A 2026 rat study found semaglutide affects gonads beyond weight loss: androgens protected in males, reproductive hormones reduced in females.
GLP-1 drugs and skin disease: the evidence
A 2026 dermatology review examines how GLP-1 receptor agonists, including tirzepatide, may affect psoriasis, hidradenitis suppurativa, acne, and wound healing.
GLP-1 Drugs and Pregnancy: A Trends Update
Real-world data show a gap between guideline recommendations and GLP-1 discontinuation timing around pregnancy. Here is what the evidence says.